These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 919363)

  • 1. [Various current problems associated with anticoagulant therapy using Pelentan].
    Donner L; Klener P
    Vnitr Lek; 1977 Sep; 23(9):880-6. PubMed ID: 919363
    [No Abstract]   [Full Text] [Related]  

  • 2. [Control of anticoagulant therapy with Pelentan. Results of the work of 20 laboratories].
    Vorlová Z; Sikorová J
    Cas Lek Cesk; 1982 Dec; 121(49):1515-7. PubMed ID: 7151121
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prothrombin time and heparin time during pelentan therapy].
    CERMAK L; HOBZA A; POKORNY J
    Pol Tyg Lek (Wars); 1956 Sep; 11(37):1577-8. PubMed ID: 13388837
    [No Abstract]   [Full Text] [Related]  

  • 4. [Control of anticoagulation therapy with Pelentan. Results of the 2nd working study of 37 laboratories].
    Vorlová Z; Sikorová J
    Cas Lek Cesk; 1983 Dec; 122(51):1569-72. PubMed ID: 6652671
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of reserpine and some adrenolytics on the anticoagulant activity of pelentan (ethylbiscoumacetate).
    Hrdina P; Kovalcík V
    Thromb Diath Haemorrh; 1967 Dec; 18(3-4):759-65. PubMed ID: 5590255
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anticoagulant treatment following thrombolytic therapy].
    Ohler WG
    Med Klin; 1966 Jan; 61(4):140-2. PubMed ID: 5983159
    [No Abstract]   [Full Text] [Related]  

  • 7. Anticoagulant therapy with tromexan and marcoumar and determination of the prothrombin-proconvertin activity by a micro-method.
    IVERSEN T
    Acta Med Scand; 1956 Sep; 155(3):161-70. PubMed ID: 13361829
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experience with prophylactic postoperative anticoagulant treatment in 6551 patients].
    Alánt O; Alexy G
    Acta Chir Acad Sci Hung; 1969; 10(2):139-50. PubMed ID: 5344314
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticoagulant activity of Heraclenin.
    Mishra KC; Sharma RC; Sharma YN; Arora RB
    Indian J Physiol Pharmacol; 1969 Jul; 13(3):153-5. PubMed ID: 5362630
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of heparin and pelentan on the biopolymer metabolism of connective tissue in myocardial infarct].
    Sharaev PN; Leshchinskiĭ LA; Pimenov LT; Vtorov AE
    Farmakol Toksikol; 1984; 47(1):44-6. PubMed ID: 6705903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [At the present level of anticoagulation therapy with Pelentan, is it possible to expect effective prevention of thromboembolism?].
    Krislo V; Sorf M; Krislová M
    Vnitr Lek; 1985 Aug; 31(8):806-9. PubMed ID: 4036034
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of anticoagulant therapy in focal ischemic cerebrovascular disease: further observations.
    Siekert RG
    Res Publ Assoc Res Nerv Ment Dis; 1966; 41():359-66. PubMed ID: 4163329
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of pelentan (ethyl dihydroxycumarinylacetate) on the level of some blood coagulation factors in relation to age].
    Nerad V; Chrobák L; Skaunic V; Hassmanová V
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1966; 9(4):605-8. PubMed ID: 5226690
    [No Abstract]   [Full Text] [Related]  

  • 14. [A case of intramural hematoma of the small bowel during anticoagulant therapy. Resection and cure].
    Gillet M; Jaeck D; Marescaux J; Weill-Bousson M; Dauchel J; Grenier JF
    Acta Chir Belg; 1972 Oct; 71(5):352-61. PubMed ID: 4659884
    [No Abstract]   [Full Text] [Related]  

  • 15. [An optimal coagulation method to determine anti-heparin compounds in biological specimens].
    Roszkowska-Jakimiec W
    Rocz Akad Med Im Juliana Marchlewskiego Bialymst; 1986-1987; 31-32():143-51. PubMed ID: 3152143
    [No Abstract]   [Full Text] [Related]  

  • 16. [Supervision of anticoagulant therapy with the aid of the factor X determination].
    Dahl J; Remde W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1966; 85(1):96-102. PubMed ID: 4165545
    [No Abstract]   [Full Text] [Related]  

  • 17. The pharmacodynamics of the oral anticoagulant drugs.
    O'Reilly RA
    Prog Hemost Thromb; 1974; 2(0):175-213. PubMed ID: 4137288
    [No Abstract]   [Full Text] [Related]  

  • 18. [Our experiences with long-term treatment with Pelentan in myocardial infarct].
    Argalás K; Rysavý F
    Vnitr Lek; 1968 Mar; 14(3):283-90. PubMed ID: 5638966
    [No Abstract]   [Full Text] [Related]  

  • 19. [Reaction determining blood prothrombin activity and control of pelentan therapy from the practical viewpoint].
    LIBANSKY J; DIENSTBIER Z; POLAK B
    Cas Lek Cesk; 1951 Aug; 90(35):1039-45. PubMed ID: 14879385
    [No Abstract]   [Full Text] [Related]  

  • 20. [Metabolism in rats following prolonged administration of pelentan (di 4-hydroxycumarinyl-3-acetic acid ethylester); studies on anticoagulant substances V].
    HAIS IM; ZABRODSKY S
    Cas Lek Cesk; 1950 Oct; 89(40):1116-20. PubMed ID: 14772872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.